Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
Karen said
Apr 17, 2013
The drugs just keep on coming....
Cinnamon Girl said
Apr 17, 2013
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
All-Oral Trial to Evaluate the Safety and Efficacy of a 12-Week Regimen of Sovaprevir, ACH-3102 and Ribavirin for Genotype 1 Treatment-Naive HCV Patients
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sovaprevir, ACH-3102, and ribavirin in patients with chronic HCV who have not received prior therapy.
The drugs just keep on coming....
Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV
All-Oral Trial to Evaluate the Safety and Efficacy of a 12-Week Regimen of Sovaprevir, ACH-3102 and Ribavirin for Genotype 1 Treatment-Naive HCV Patients
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sovaprevir, ACH-3102, and ribavirin in patients with chronic HCV who have not received prior therapy.
Link to media release...
http://ir.achillion.com/releasedetail.cfm?ReleaseID=756688